Haineng Xu, PhD

Haineng Xu, PhD

Dr. Haineng Xu is a postdoctoral researcher at the Ovarian Cancer Research Center at the University of Pennsylvania. Dr. Xu graduated from Chinese Academy of Sciences, where his research focus was on designing and optimizing the conditionally replicated adenovirus to specially suppress liver cancer cells and lung cancer stem cells, utilizing small molecular drugs to target gastric cancer stem cells. Dr. Xu is currently working under the supervision of Dr. Fiona Simpkins to develop novel therapeutic strategies by exploiting the genetic vulnerabilities in ovarian cancer. Combination of WEE1 and ATR inhibition was explored to treat the PARP inhibitor- and platinum- resistant, CCNE1 overexpressing ovarian cancers. The novel orthotopic patient-derived xenograft models are utilized in the preclinical trials to evaluate the drug efficacy and the mice tolerability. Treatment schedule optimization of the combination of WEE1 and ATR inhibitors further improve its efficacy and drug tolerance of the mice. The ultimate goal is to identify new therapies for women with ovarian cancer in the lab and bring them to the clinic.